布非化瘀汤（BFHY）是一种临床处方，据报道在增强非小细胞肺癌（NSCLC）化疗药物疗效方面具有功效。然而，BFHY作用的潜在代谢机制尚未被探索。本研究的目的是研究顺铂和顺铂加BFHY对NSCLC的整体代谢影响。NSCLC、顺铂和顺铂+BFHY三个组别在基于UHPLC-QE-MS的血清代谢组学程序下接受了实验。然后，使用MetaboAnalyst 3.0进行途径分析，以阐明顺铂和顺铂加BFHY在NSCLC中的治疗作用途径。在皮下NSCLC模型中，顺铂和顺铂+BFHY都减小了肿瘤体积并引起了细胞死亡。与顺铂单独相比，顺铂+BFHY表现出更强的抑制肿瘤的影响。此外，顺铂和顺铂+BFHY治疗共有16条代谢信号通路。这些典型代谢物主要涉及氨基酸代谢、脂质动员、核酸代谢和碳水化合物代谢。我们的研究揭示了顺铂和顺铂+BFHY反肿瘤作用的潜在生物标志物和代谢网络。© 2023 The Authors. Published by Elsevier Ltd.

Bufei Huayu Decoction (BFHY) is a clinical prescription with reported efficacy in enhancing the therapeutic outcomes of chemotherapeutic agents for non-small cell lung cancer (NSCLC). However, the underlying metabolic mechanism of BFHY's action remains unexplored.The objective of this study is to investigate the global metabolic effects of cisplatin and cisplatin plus BFHY on NSCLC.Three groups (NSCLC, cisplatin, and cisplatin + BFHY) underwent a serum metabolomics procedure based on UHPLC-QE-MS. Then, a pathway analysis was carried out using MetaboAnalyst 3.0 to elucidate the therapeutic action routes of cisplatin and cisplatin plus BFHY in NSCLC.In the subcutaneous NSCLC model, both cisplatin and cisplatin + BFHY reduced the tumor volume and caused cell death. In comparison to cisplatin alone, cisplatin + BFHY showed a stronger tumor-suppressing impact. Furthermore, the same 16 metabolic signaling pathways were shared by the cisplatin and cisplatin + BFHY treatments. These typical metabolites are mainly involved in amino acid metabolism, lipid mobilization, nucleic acid metabolism and carbohydrate metabolites.Potential biomarkers and metabolic networks of cisplatin and cisplatin + BFHY's anti-tumor actions are revealed in our investigation.© 2023 The Authors. Published by Elsevier Ltd.